News

Lupin Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Lupin Limited announced that its Operations and Finance Committee has allotted 24111 fully paid-up equity shares of Rs 2/- each, following the exercise of vested options granted to employees of the company and its subsidiaries under its stock option plans, increasing the issued and paid-up share capital to Rs 91,45,79,944 consisting of 45,72,89,972 equity shares of Rs 2/- each.

Lupin Limited announced that its Operations and Finance Committee has allotted 30967 fully paid-up equity shares of Rs 2 each, increasing the company`s issued and paid-up share capital to Rs 91,45,31,722 consisting of 45,72,65,861 equity shares of Rs 2 each, following the exercise of vested options under the company`s stock option plans for employees and its subsidiaries.

Lupin announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet. The U.S. FDA has approved Lupin`s Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet as bioequivalent to the reference listed drug (RLD) Lokelma� for Oral Suspension of AstraZeneca Pharmaceuticals LP and is indicated for the treatment of hyperkalemia in adults. Sodium Zirconium Cyclosilicate for Oral Suspension (RLD Lokelma�) had estimated annual sales of USD 568 million in the U.S. (IQVIA MAT Jun 2026).

Net profit of Lupin rose 16.08% to Rs 1415.00 crore in the quarter ended June 2026 as against Rs 1219.03 crore during the previous quarter ended June 2025. Sales rose 33.32% to Rs 8217.23 crore in the quarter ended June 2026 as against Rs 6163.75 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales8217.236163.75 33 OPM %29.8128.02 - PBDT2470.211714.52 44 PBT2017.361415.54 43 NP1415.001219.03 16 Powered by Capital Market - Live News